Hlib Chabaniuk

Pacific Biosciences of California unveils HiFi sequencing to identify rare disease cases missed by standard tests

Pacific Biosciences of California unveils HiFi sequencing to identify rare disease cases missed by standard tests
PacBio HiFi targets rare disease gaps

Pacific Biosciences of California is advancing genomic medicine by introducing HiFi sequencing as a solution for rare disease cases that remain unexplained after standard genetic tests.

The company brings together an expert panel to discuss how this technology can uncover genetic variations that traditional methods overlook. Along with the panel, Pacific Biosciences of California offers access to a new white paper detailing solve rates in rare disease investigations. Details about the technology, data, and opportunities for clinicians and researchers are available through the company's online resources.

Pacific Biosciences of California recently drew interest with packed sessions and booth events at ESHG2026. The company has also made PRISM 2026 conference presentations available on demand. These efforts expand Pacific Biosciences of California's outreach to researchers and clinicians.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.